Gynuity’s TelAbortion Study Will Stop Enrolling at the End of this Month
Gynuity’s TelAbortion Study – a groundbreaking research project designed to evaluate the use of telemedicine for providing medical abortion in the U.S. – will stop enrolling at the end of this month.
We launched the TelAbortion study in 2016 at a time when telemedicine abortion was a newly emerging idea with little documentation available for policymakers. In addition, Food and Drug Administration (FDA) dispensing restrictions prohibited the mailing of abortion pills outside of our study setting.
Five years down the line, it now seems the right time to move on and ask new questions.
Our research has shown that this model of early medical abortion care, which allows abortion-seekers to be counselled remotely and receive the medications through the mail, is safe, efficacious and acceptable.
Our recent paper summarizing the expansion of the TelAbortion study during the COVID-19 pandemic, when we saw usage double, demonstrated that outcomes are comparable to in-clinic care and the service is highly effective. This paper was the primary source cited in the FDA’s decision to suspend the in-person mifepristone dispensing requirements for the duration of the pandemic. The FDA is now reviewing the full range of restrictions currently placed on mifepristone.
We have created a legacy that will impact positively the lives of abortion-seekers in the U.S., increasing options for those who have trouble getting to a clinic. Participants in our study report being very satisfied, and consistently note that privacy and convenience are the best features of this service.
We are extremely proud of what we have achieved in partnership with clinical providers across the U.S. None of this work would have been possible without them. We are delighted that this direct-to-user telemedicine abortion service will continue to be offered beyond our research project.
At Gynuity, we will carry on fulfilling our mission, examining innovative ways to expand safe and effective reproductive and maternal healthcare access. Watch this space!